ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $257,000 | -98.0% | 4,300 | -96.2% | 0.05% | -94.6% |
Q1 2021 | $12,775,000 | +1798.2% | 112,200 | +1204.7% | 0.97% | +1461.3% |
Q2 2020 | $673,000 | +71.2% | 8,600 | -4.9% | 0.06% | +17.0% |
Q4 2018 | $393,000 | -43.1% | 9,047 | 0.0% | 0.05% | -27.4% |
Q3 2018 | $691,000 | – | 9,047 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |